Journals / Respiratory Case Reports / 2022 / Cilt: 11 - Sayı: 1

Rare Interstitial Pneumonia Due to the Use of Aripiprazol: A Case Report

Aripiprazol Kullanımına Bağlı Nadir Görülen İnterstisyel Pnömoni: Olgu Sunumu

Pages
44–49
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present this case to increase awareness of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It is accepted that 2–3% of interstitial lung diseases (ILD) are due to drugs, and that 70% of drug-induced lung diseases are due to ILD.
📊
Key Findings & Data:We present here the case of a 51-year-old female patient who had been taking aripiprazole for bipolar disorder for 3 years and had been undergoing asthma treatment for 2 years.
💡
Conclusion & Impact:We present this case to increase awareness of the disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It is accepted that 2–3% of interstitial lung diseases (ILD) are due to drugs, and that 70% of drug-induced lung diseases are due to ILD. We present here the case of a 51-year-old female patient who had been taking aripiprazole for bipolar disorder for 3 years and had been undergoing asthma treatment for 2 years. ILD was considered based on the patient's clinic, a restrictive pattern in the pulmonary function test (PFT), a decreased carbon monoxide diffusion test, laboratory results, radiological findings and biopsy. The possible etiologies of infection, aspiration, heart failure, pet feeding status and exposure to haz-ardous respiratory substances were excluded. The suspected drug was discontinued and oral cortico-steroid treatment was started. Lung toxicity can devel-op with drug treatments, and so drug history should be questioned in detail and discontinued immediately in case of any doubt. ILD is rare, and if the drug is not suspected and continued, the disease may be-come chronic and progress to respiratory failure. We present this case to increase awareness of the disease.

Özet

İnterstisyel akciğer hastalıklarının (IAH) %2-3'unun ilaçlara bağlı olduğu ve ilaca bağlı akciğer hastalık-larının %70'inin IAH'dan olduğu kabul edilmektedir. Elli bir yaşında kadın hasta 3 yıldır bipolar bozukluk için aripiprazol kullanmakta ve 2 yıldır astım tedavisi görmekteydi. Hastanın kliniği, solunum fonksiyon testinde (SFT) restriktif patern olması, azalmış karbon monoksit difüzyon testi, laboratuvar sonuçları, radyo-lojik bulguları ve biyopsi ile IAH düşünüldü. Olası etiyolojiler: enfeksiyon, aspirasyon, kalp yetmezliği, evcil hayvan besleme durumu, tehlikeli solunum maddelerine maruziyet dışlandı. Şüpheli ilaç kesile-rek, oral kortikosteroid tedavisi başlandı. İlaç tedavi-leri ile akciğer toksisitesi gelişebilir. İlaç öyküsü ayrın-tılı olarak sorgulanmalı ve şüphe durumunda derhal kesilmelidir. IAH nadir görülür; ilaçtan şüphelenilmez de devam edilirse hastalık kronikleşebilir ve solunum yetmezliğine ilerleyebilir. Hastalıkla ilgili farkındalığı artırmak için bu olguyu sunmaya amaçladık.

🔖

Cite This Article

POYRAZ, M., ALPAGAT, G., BACCIOĞLU, A., YALİM, S. A., DUMANOĞLU, B., KALPAKLIOĞLU, A. F. (2022). Rare Interstitial Pneumonia Due to the Use of Aripiprazol: A Case Report. Respiratory Case Reports, Cilt: 11 - Sayı: 1, 44–49. https://ajindex.com/articles/588870

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J 2012; 6:63-74. [CrossRef] 2. Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneu-monia/ fibrosis. Histologic features and clinical signifi-cance. Am J Surg Pathol 1994; 18:136-47. [CrossRef] 3. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, Euro-pean Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idio-pathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198: e44-e68.) [CrossRef] 4. Myers JL. Reprint of: Nonspecific interstitial pneumonia: Pathologic features and clinical implications. Semin Di-agn Pathol 2018; 35:334-8. [CrossRef] 5. Croxtall JD. Aripiprazole: a review of its use in the mana-gement of schizophrenia in adults. CNS Drugs 2012; 26:155-83. [CrossRef] 6. Gunasekaran K, Murthi S, Jennings J, Lone N. Aripipra-zole-induced hypersensitivity pneumonitis. BMJ Case Rep 2017; 2017: bcr2017-219929. [CrossRef] 7. Ben-Noun L. Drug-induced respiratory disorders: inci-dence, prevention and management. Drug Saf. 2000; 23:143-64. [CrossRef] 8. Janz DR, O'Neal HR Jr, Ely EW. Acute eosinophilic pneumonia: A case report and review of the literature. Crit Care Med 2009; 37:1470-4. [CrossRef] 9. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumo-nias. Am J Respir Cri. Care Med 2002; 165:277-304. [CrossRef] 10. Romagnoli M, Bigliazzi C, Casoni G, Chilosi M, Carloni A, Dubini A, et al. The role of transbronc-hial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:36-45. 11. Topcu F, Akyildiz L. Lung diseases due to nonche-motherapeutic drugs. In: Ozlu T, Metintas M, Ka-radag M, Kaya A, eds. Respiratory system and di-seases basic reference book Vol 2. Istanbul: Istan-bul Medical Bookstore; 2010: 2505-30. 12. Ulubas B, Sahin G, Ozer C, Aydin O, Ozgür E, Apaydin D. Bronchiolitis obliterans organizing pne-umonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004; 23:249-51. [CrossRef] 13. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292-